Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety

被引：0

作者：

Lonial, Sagar

Jagannath, Sundar

Moreau, Philippe

Jakubowiak, Andrzej J.

Raab, Marc S.

Facon, Thierry

Vij, Ravi

Bleickardt, Eric

Reece, Donna Ellen

Benboubker, Lotfi

Zonder, Jeffrey A.

Deng, Wei

Singhal, Anil K.

Richardson, Paul Gerard Guy

机构：

[1] Emory Univ, Sch Med, Atlanta, GA USA

[2] Multiple Myeloma Res Consortium, Norwalk, CT USA

[3] Mt Sinai Med Ctr, New York, NY 10029 USA

[4] Univ Hosp Hotel Dieu, Nantes, France

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Univ Klinikum Heidelberg, Heidelberg, Germany

[7] Hop Claude Huriez, Lille, France

[8] Washington Univ, Sch Med, St Louis, MO USA

[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[10] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[11] Hop Bretonneau, Ctr Hosp Univ Tours, Tours, France

[12] Karmanos Canc Inst, Detroit, MI USA

[13] AbbVie Biotherapeut Inc, Redwood City, CA USA

[14] AbbVie Biotherapeut Corp, Redwood City, CA USA

[15] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8542

引用

页数：1